About: Antibiotics in acute bronchitis: a meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antibiotics in acute bronchitis: a meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antibiotics in acute bronchitis: a meta-analysis
Source	Elsevier; Medline; PMC
abstract	Abstract PURPOSE: Most patients with acute bronchitis who seek medical care are treated with antibiotics, although the effectiveness of this intervention is uncertain. We performed a meta-analysis of randomized, controlled trials to estimate the effectiveness of antibiotics in the treatment of acute bronchitis. SUBJECTS AND METHODS: English-language studies published January 1966 to April 1998 were retrieved using MEDLINE, bibliographies, and consultation with experts. Only randomized trials that enrolled otherwise healthy patients with a diagnosis of acute bronchitis, used an antibiotic in the treatment group and a placebo in the control group, and provided sufficient data to calculate an effect size were included. RESULTS: We identified eight randomized controlled trials that satisfied all inclusion criteria. These studies used one of three antibiotics (erythromycin, doxycycline, trimethoprim/sulfamethoxazole). The use of antibiotics decreased the duration of cough and sputum production by approximately one-half day (summary effect size 0.21; 95% CI, 0.05 to 0.36). For specific symptoms, there were nonsignificant trends favoring the use of antibiotics: a decrease of 0.4 days of purulent sputum (95% CI, −0.1 to 0.8), a decrease of 0.5 days of cough (95% CI, −0.1 to 1.1), and a decrease of 0.3 days lost from work (95% CI, −0.6 to 1.1). CONCLUSION: This meta-analysis suggests a small benefit from the use of the antibiotics erythromycin, doxycycline, or trimethoprim/sulfamethoxazole in the treatment of acute bronchitis in otherwise healthy patients. As this small benefit must be weighed against the risk of side effects and the societal cost of increasing antibiotic resistance, we believe that the use of antibiotics is not justified in these patients.
has issue date	1999-07-31(xsd:dateTime)
bibo:doi	10.1016/s0002-9343(99)00167-9
bibo:pmid	10403354
has license	els-covid
sha1sum (hex)	c0c8280395b9ac6b028ef64dd7a64ee05213bcae
schema:url	https://doi.org/10.1016/s0002-9343%2899%2900167-9
resource representing a document's title	Antibiotics in acute bronchitis: a meta-analysis
has PubMed Central identifier	PMC7124195
has PubMed identifier	10403354
schema:publication	The American Journal of Medicine
resource representing a document's body	covid:c0c8280395b9ac6b028ef64dd7a64ee05213bcae#body_text
is schema:about of	named entity 'correlation' named entity 'antibiotics' named entity 'MEDLINE' named entity 'pulmonary disorders' named entity 'bronchitis' named entity 'sputum' named entity 'sample sizes' named entity 'meta-analysis' named entity 'cough' named entity 'meta-analysis' named entity '10 million' named entity 'outcome measure' named entity 'antibiotic resistance' named entity 'randomized controlled trials' named entity 'sputum production' named entity 'treatment group' named entity 'statistically significant' named entity 'publication bias' named entity 'United States' named entity 'variance' named entity 'antibiotic treatment' named entity 'Randomized controlled trials' named entity 'meta-analysis' named entity 'antibiotic treatment' named entity 'cough' named entity 'antibiotics' named entity 'erythromycin' named entity 'antibiotics' named entity 'risks and benefits' named entity '0.21' named entity 'effect size' named entity '95% CI' named entity 'effect sizes' named entity 'Legionella' named entity 'acute bronchitis' named entity 'placebo' named entity 'antibiotics' named entity 'effect size' named entity 'antibiotics' named entity 'placebo' named entity 'symptom' named entity 'coronavirus' named entity 'antibiotics' named entity 'sputum production' named entity 'confidence intervals' named entity 'cough' named entity 'antibiotics' named entity 'pneumonia' named entity 'antibiotics' named entity 'randomized trials' named entity 'cough' named entity 'acute bronchitis' named entity 'antibiotics' named entity 'statistical tests' named entity 'randomized trials' named entity 'sputum production' named entity 'statistically significant' named entity 'antibiotic therapy' named entity 'antibiotics' named entity 'Atypical bacteria' named entity '95% CI' named entity 'sputum production' named entity 'viruses' named entity 'statistical significance' named entity 'publication bias' named entity 'placebo' named entity 'publication bias' named entity 'Chlamydia pneumoniae' named entity 'acute bronchitis' named entity 'parainfluenza' named entity 'acute bronchitis' named entity 'cough' named entity 'acute bronchitis' named entity 'antihistamines' named entity 'dura' named entity 'acute bronchitis' named entity 'antibiotic resistance' named entity 'negative results' named entity 'antibiotics' named entity 'outcome measure' named entity 'correlation' named entity 'randomly assigned'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software